Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
This phase 2 trial investigates the activity and safety of enobosarm, an oral selective androgen receptor modulator (SARM), in patients with androgen receptor-positive, estrogen receptor-positive, and HER2-negative advanced breast cancer. The study found that enobosarm demonstrated promising efficacy in improving clinical outcomes with manageable safety risks. These results support further
June 26, 2025
No Comments